As of Nov 19, 2026, 1 of 1 active firms rate ICCM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ICCM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.84
Range $-0.84 – $-0.84 · 1 analysts · -53% YoY
Next period, 1 analysts expect Icecure Medical to earn $-0.84 a share (range $-0.84 – $-0.84), versus $-1.80 a year earlier. Full-year consensus is $-4.61, growing to $-3.44 the year after.
REVENUE · NEXT QUARTER
$1.6M
Range $1.5M – $1.7M · 1 analysts · +25% YoY
Revenue is expected to reach $1.6M (range $1.5M – $1.7M), +25.1% year-over-year. Full-year consensus is $4.3M, rising to $8.8M next year.
Top analysts covering Icecure Medical
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ICCM.
#1
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$75.00+7257.3% to target
Overall win rate
34%
+ Follow
#2
Anthony Vendetti
Maxim Group · Rank #456
Buy
$10.00+881.0% to target
Overall win rate
28%
+ Follow
#3
KD
Kemp Dolliver
Brookline Capital Markets
Buy
$73.50+7110.1% to target
Coverage
—
+ Follow
#4
SH
Scott Henry
Alliance Global Partners
Buy
$30.00+2842.9% to target
Coverage
—
+ Follow
ICCM stock forecast FAQ
What is ICCM's average 12-month price target?+
The 1 active firms with a live target average $1.00 for Icecure Medical over the next 12 months, ranging from a $1.00 high to a $1.00 low, as of Nov 19, 2026.
Is ICCM stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ICCM?+
1 active firms have a recognized rating on Icecure Medical as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ICCM?+
Among analysts who currently cover ICCM, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #350). Their current call is Buy with a $75.00 target.
What is Icecure Medical's projected EPS for next quarter?+
The consensus estimate is $-0.84 per share (range $-0.84 – $-0.84) across 1 analysts. Full-year EPS is projected at $-4.61, rising to $-3.44 the following year.
How much revenue is Icecure Medical expected to report next quarter?+
Consensus revenue is $1.6M (range $1.5M – $1.7M). Full-year revenue is projected at $4.3M, growing to $8.8M next year.
Have analysts been upgrading or downgrading ICCM lately?+
As of Nov 19, 2026, 1 of 1 active firms rate ICCM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ICCM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.